NEWS Dean A. Wetherbee 11/14/24 Dean A. Wetherbee 11/14/24 Thetis Pharmaceuticals Announces Appointment of Fabio Cataldi, M.D., to Board of Managers and Scientific Advisory Board Read More Dean A. Wetherbee 10/31/24 Dean A. Wetherbee 10/31/24 Thetis Pharmaceuticals Announces Positive Results From Phase 1a Study of TP-317 in Healthy Subjects Read More Dean A. Wetherbee 4/4/24 Dean A. Wetherbee 4/4/24 Thetis Pharmaceuticals Commences Phase 1a Clinical Trial with TP-317, an Oral Resolvin E1 Drug Targeting the LTB4-BLT1 Pathway Read More Dean A. Wetherbee 3/12/24 Dean A. Wetherbee 3/12/24 Thetis Pharmaceuticals Announces U.S. Patent for Treatment of Colon Cancer Read More Dean A. Wetherbee 1/16/24 Dean A. Wetherbee 1/16/24 Thetis Pharmaceuticals Progressing to Clinic with a Phase 1a Trial of TP-317, an Oral Agonist of BLT1, in Healthy Subjects Read More Dean A. Wetherbee 11/7/23 Dean A. Wetherbee 11/7/23 Mario Sznol, MD, Leader of the Melanoma Clinical Research Team at the Yale Cancer Center, Joins Thetis Scientific Advisory Board Read More Dean A. Wetherbee 10/12/23 Dean A. Wetherbee 10/12/23 Thetis Pharmaceuticals Announces Patent Issuance in Australia for First-in-Class RvE1 Drug Candidate that Targets the LTB4-BLT1 Pathway Read More Dean A. Wetherbee 10/4/23 Dean A. Wetherbee 10/4/23 Thetis Pharmaceuticals Announces Poster Presentation at 2023 AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics Read More Dean A. Wetherbee 7/24/23 Dean A. Wetherbee 7/24/23 Joyce Steinberg, MD, FACP, Board-Certified Oncologist and Biopharma Industry Veteran, Joins Thetis Pharmaceuticals Read More Dean A. Wetherbee 7/10/23 Dean A. Wetherbee 7/10/23 John Parkinson, PhD, Immunologist and Biopharma Industry Veteran, Appointed Chief Scientific Officer of Thetis Pharmaceuticals Read More Dean A. Wetherbee 6/13/23 Dean A. Wetherbee 6/13/23 Thetis Forms Australia Subsidiary to Investigate First-in-Class Oral Resolvin E1 Drug (TP-317) for Moderate-to-Severe IBD Read More Dean A. Wetherbee 6/2/23 Dean A. Wetherbee 6/2/23 Thetis Announces $2.4 Million SBIR Grant from the NIH to Develop Small Molecule BLT1 Agonist to Treat Pancreatic Cancer Read More Dean A. Wetherbee 4/5/23 Dean A. Wetherbee 4/5/23 Thetis Pharmaceuticals Cancer Program to be Presented at the American Association of Cancer Research (AACR) Annual Meeting Read More Dean A. Wetherbee 3/15/23 Dean A. Wetherbee 3/15/23 Thetis Announces $3 Million SBIR Grant from the NIH to Develop Oral Therapy for Moderate-to-Severe IBD Read More Dean A. Wetherbee 8/24/22 Dean A. Wetherbee 8/24/22 Thetis Pharmaceuticals Announces Patent Issuance in Korea for First-in-Class Resolvin E1 Drug Read More Dean A. Wetherbee 6/15/22 Dean A. Wetherbee 6/15/22 Thetis Pharmaceuticals Announces Patent Issuance in China for First-in-Class Resolvin E1 Drug Read More Dean A. Wetherbee 4/5/22 Dean A. Wetherbee 4/5/22 Thetis Pharmaceuticals Secures $4.2 Million From the Helmsley Charitable Trust to Advance Its First-in-Class, Oral Resolvin E1 Therapy for Crohn’s Disease Read More
Dean A. Wetherbee 11/14/24 Dean A. Wetherbee 11/14/24 Thetis Pharmaceuticals Announces Appointment of Fabio Cataldi, M.D., to Board of Managers and Scientific Advisory Board Read More
Dean A. Wetherbee 10/31/24 Dean A. Wetherbee 10/31/24 Thetis Pharmaceuticals Announces Positive Results From Phase 1a Study of TP-317 in Healthy Subjects Read More
Dean A. Wetherbee 4/4/24 Dean A. Wetherbee 4/4/24 Thetis Pharmaceuticals Commences Phase 1a Clinical Trial with TP-317, an Oral Resolvin E1 Drug Targeting the LTB4-BLT1 Pathway Read More
Dean A. Wetherbee 3/12/24 Dean A. Wetherbee 3/12/24 Thetis Pharmaceuticals Announces U.S. Patent for Treatment of Colon Cancer Read More
Dean A. Wetherbee 1/16/24 Dean A. Wetherbee 1/16/24 Thetis Pharmaceuticals Progressing to Clinic with a Phase 1a Trial of TP-317, an Oral Agonist of BLT1, in Healthy Subjects Read More
Dean A. Wetherbee 11/7/23 Dean A. Wetherbee 11/7/23 Mario Sznol, MD, Leader of the Melanoma Clinical Research Team at the Yale Cancer Center, Joins Thetis Scientific Advisory Board Read More
Dean A. Wetherbee 10/12/23 Dean A. Wetherbee 10/12/23 Thetis Pharmaceuticals Announces Patent Issuance in Australia for First-in-Class RvE1 Drug Candidate that Targets the LTB4-BLT1 Pathway Read More
Dean A. Wetherbee 10/4/23 Dean A. Wetherbee 10/4/23 Thetis Pharmaceuticals Announces Poster Presentation at 2023 AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics Read More
Dean A. Wetherbee 7/24/23 Dean A. Wetherbee 7/24/23 Joyce Steinberg, MD, FACP, Board-Certified Oncologist and Biopharma Industry Veteran, Joins Thetis Pharmaceuticals Read More
Dean A. Wetherbee 7/10/23 Dean A. Wetherbee 7/10/23 John Parkinson, PhD, Immunologist and Biopharma Industry Veteran, Appointed Chief Scientific Officer of Thetis Pharmaceuticals Read More
Dean A. Wetherbee 6/13/23 Dean A. Wetherbee 6/13/23 Thetis Forms Australia Subsidiary to Investigate First-in-Class Oral Resolvin E1 Drug (TP-317) for Moderate-to-Severe IBD Read More
Dean A. Wetherbee 6/2/23 Dean A. Wetherbee 6/2/23 Thetis Announces $2.4 Million SBIR Grant from the NIH to Develop Small Molecule BLT1 Agonist to Treat Pancreatic Cancer Read More
Dean A. Wetherbee 4/5/23 Dean A. Wetherbee 4/5/23 Thetis Pharmaceuticals Cancer Program to be Presented at the American Association of Cancer Research (AACR) Annual Meeting Read More
Dean A. Wetherbee 3/15/23 Dean A. Wetherbee 3/15/23 Thetis Announces $3 Million SBIR Grant from the NIH to Develop Oral Therapy for Moderate-to-Severe IBD Read More
Dean A. Wetherbee 8/24/22 Dean A. Wetherbee 8/24/22 Thetis Pharmaceuticals Announces Patent Issuance in Korea for First-in-Class Resolvin E1 Drug Read More
Dean A. Wetherbee 6/15/22 Dean A. Wetherbee 6/15/22 Thetis Pharmaceuticals Announces Patent Issuance in China for First-in-Class Resolvin E1 Drug Read More
Dean A. Wetherbee 4/5/22 Dean A. Wetherbee 4/5/22 Thetis Pharmaceuticals Secures $4.2 Million From the Helmsley Charitable Trust to Advance Its First-in-Class, Oral Resolvin E1 Therapy for Crohn’s Disease Read More
